Biohaven’s Nurtec May Be First Migraine Drug For Acute Treatment And Prevention

Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.

Drugs for migraine treatment
Nurtec ODT could be the first oral anti-CGRP drug for migraine prevention • Source: Shutterstock

Biohaven Pharmaceutical Holding Co. Ltd. was the third company to bring a new drug for acute treatment of migraine attacks to the US market after two decades with no new on-demand therapies, but based on positive results from the latest Phase III clinical trial for Nurtec (rimegepant) it could be the first firm to win US Food and Drug Administration approval for an oral preventive therapy and the first with a dual purpose migraine medicine on the market.

The company plans to submit a supplemental new drug application to the US FDA by mid-year after reporting positive Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category